Share price · PLUR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PLUR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 26 Oct 2026+13.1%
Nothing announced by PLUR that day or the session before.
- 21 Oct 2026+16.7%
- 19 Oct 2026-8.6%
Nothing announced by PLUR that day or the session before.
- 9 Sep 2026+7.9%
Nothing announced by PLUR that day or the session before.
- 26 Aug 2026-10.8%
Nothing announced by PLUR that day or the session before.
- 24 Aug 2026-8.8%
Nothing announced by PLUR that day or the session before.
- 5 Aug 2026+11.5%
Nothing announced by PLUR that day or the session before.
- 26 Jun 2026-6.0%
Nothing announced by PLUR that day or the session before.
- 18 Jun 2026-10.2%
Nothing announced by PLUR that day or the session before.
- 21 May 2026-11.5%
Nothing announced by PLUR that day or the session before.
Share of unusual movement by asset
For each asset, the share of PLUR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 13% |
| Sessions with no dated event | — | 87% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
PLX-PADNo recent activity | Preclinical / Unstaged | Mesenchymal stem cells (immunomodulatory, pro-angiogenic)Cell therapy | Osteoarthritis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.8M | $14M | $4.5M+ $5.3M short-term inv. | $10M-$4.5M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0.2M | $4.0M | $4.6M+ $7.1M short-term inv. | $5.5M-$4.5M operating cash flow | report ↗ |
| 2025-Q4 | $0.2M | $3.8M | $5.8M+ $9.0M short-term inv. | $6.5M-$5.2M operating cash flow | report ↗ |
| 2025-Q3 | $0.3M | $3.9M | $5.6M+ $12M short-term inv. | $5.8M-$5.4M operating cash flow | report ↗ |
| 2025-Q1 | $0.4M | $3.0M | $9.7M+ $19M short-term inv. | $6.2M-$4.3M operating cash flow | report ↗ |
| 2024-Q4 | $0.2M | $2.9M | $8.3M+ $15M short-term inv. | $3.0M-$4.6M operating cash flow | report ↗ |
| 2024-Q3 | $0.3M | $2.9M | $4.2M+ $23M short-term inv. | $5.9M-$4.1M operating cash flow | report ↗ |
| 2024-Q1 | $0.1M | $3.1M | $8.0M+ $20M short-term inv. | $5.3M-$4.2M operating cash flow | report ↗ |
| 2023-Q4 | $0.1M | $3.0M | $6.5M | $4.9M-$3.6M operating cash flow | report ↗ |
| 2023-Q3 | $0.1M | $3.4M | $6.2M | $5.0M-$5.9M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $4.3M | $4.6M | $7.6M-$6.1M operating cash flow | report ↗ |
| 2022-Q4 | $0 | $4.6M | $10M | $8.1M-$6.3M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $4.5M | $10M | $6.1M-$7.6M operating cash flow | report ↗ |
| 2022-Q1 | $0.2M | $6.3M | $25M | $9.9M-$9.4M operating cash flow | report ↗ |
| 2021-Q4 | — | $6.5M | $19M+ $39M short-term inv. | $11M-$9.9M operating cash flow | report ↗ |
| 2021-Q3 | — | $6.4M | $15M+ $46M short-term inv. | $11M-$8.8M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $1.0M | $15M | $4.6M+ $5.3M short-term inv. | $6.0M-$20M operating cash flow | report ↗ |
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.3M | $13M | $7.2M+ $16M short-term inv. | $5.7M-$18M operating cash flow | report ↗ |
| 2024-FY | $0.3M | $12M | $7.7M+ $24M short-term inv. | $5.2M-$18M operating cash flow | report ↗ |
| 2023-FY | $0.3M | $17M | $6.3M | $7.1M-$23M operating cash flow | report ↗ |
| 2022-FY | $0.2M | $25M | $11M | $10M-$37M operating cash flow | report ↗ |
| 2021-FY | — | $31M | $32M+ $34M short-term inv. | $12M-$31M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($1.3M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-23 | Manieu Alexandre Weinstein · director, 10% owner | Open-market purchase | 833,334 | $1.50 | $1.3M | Form 4 |
| 2026-10-23 | Manieu Alexandre Weinstein · director, 10% owner | Open-market purchase (derivative) | 833,334 | — | — | Form 4 |
| 2026-08-25 | Manieu Alexandre Weinstein · director, 10% owner | Option exercise | 641 | — | — | Form 4 |
| 2026-08-20 | Manieu Alexandre Weinstein · director, 10% owner | Award / grant | 180,000 | — | — | Form 4 |
| 2026-08-20 | SHORRER DORON · director | Award / grant | 31,569 | — | — | Form 4 |
| 2026-06-30 | Manieu Alexandre Weinstein · director, 10% owner | Award / grant | 641 | — | — | Form 4 |
| 2026-06-30 | Manieu Alexandre Weinstein · director, 10% owner | Code E (derivative) | 625,000 | — | — | Form 4 |
| 2026-04-21 | Manieu Alexandre Weinstein; Chutzpah Holdings Ltd · director, 10% owner; 10% owner | Award / grant | 312,500 | $2.00 | $625K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 14 reporting institutions held 0.0M shares ($91K, 0.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 19,424 | $66K |
| 2 | MORGAN STANLEY | 3,076 | $10K |
| 3 | EverSource Wealth Advisors, LLC | 2,000 | $7K |
| 4 | CITIGROUP INC | 1,360 | $5K |
| 5 | SIMA Wealth Partners, LLC | 350 | $1K |
| 6 | WELLS FARGO & COMPANY/MN | 185 | $628 |
| 7 | JPMORGAN CHASE & CO | 125 | $420 |
| 8 | SBI Securities Co., Ltd. | 97 | $329 |
| 9 | UBS Group AG | 95 | $322 |
| 10 | TD Waterhouse Canada Inc. | 93 | $312 |
| 11 | OSAIC HOLDINGS, INC. | 50 | $170 |
| 12 | Winch Advisory Services, LLC | 26 | $88 |
| 13 | TFC Financial Management, Inc. | 19 | $65 |
| 14 | ROYAL BANK OF CANADA | 125 | $0 |